【Abstract】ObjectiveTo investigate the efficacy of rosuvastatin combined with trimetazidine in the treatment of chronic heart failure (CHF) and its affect on the levels of serum inflammatory factors and plasma endothelin. MethodsA total of 92 CHF patients who were hospitalized in Huangchuan County People′s Hospital from February 2013 to July 2016 were selected and divided into observation group and control group according to the random number table, with 46 cases in each group. Both groups were treated with conventional treatment, and the control group was treated with trimetazidine on the basis of conventional treatment, while the observation group was treated with trimetazidine and rosuvastatin on the basis of conventional treatment. The clinical efficacy and adverse reaction were compared between the two groups; the levels of serum inflammatory cytokines, plasma endothelin (ET) and B  type brain natriuretic peptide (BNP) of the two groups were measured before and after treatment. ResultsThe total effective rate of the observation group (93.48%) was significantly higher than that in the control group (78.26%, P＜0.05). After treatment, the levels of TNFα, IL6, IL17, ET and BNP in observation group were significantly lower than those in the control group（P＜0.05）. No significant difference was found between two groups in adverse reaction(P＞0.05). ConclusionsOn the basis of conventional therapy, rosuvastatin combined with trimetazidine on the treatment of patients with CHF can effectively alleviate inflammation, reduce the levels of serum ET and BNP, and the effect is significant, and have good safety.

无